Akums Drugs & Pharmaceuticals Reports ₹11.6 Billion Revenue and ₹663.2 Million Net Profit in Q3 FY26

Akums Drugs & Pharmaceuticals Ltd, India’s largest contract development and manufacturing organization (CDMO), has reported robust financial results for the December quarter (Q3 FY26). The company posted consolidated revenue from operations of ₹11.6 billion, alongside a consolidated net profit of ₹663.2 million.

This performance underscores Akums’ ability to leverage scale, innovation, and partnerships to meet rising demand across domestic and international markets. The company’s diversified portfolio of pharmaceutical formulations, strong client base, and focus on operational efficiency have contributed to improved margins and sustainable growth.

Key Highlights

• Revenue Performance: Consolidated revenue from operations stood at ₹11.6 billion in Q3 FY26.
• Profitability: Consolidated net profit reached ₹663.2 million.
• Operational Efficiency: Margins supported by scale, cost optimization, and execution excellence.
• Business Strength: Growth driven by demand in formulations and contract manufacturing services.
• Market Positioning: Reinforces Akums’ leadership in India’s pharmaceutical CDMO sector.
• Future Outlook: Diversified client base and global expansion expected to sustain momentum.

Akums’ results reflect its strategic focus on innovation, efficiency, and market diversification. With India’s pharmaceutical industry expanding rapidly and global demand for reliable CDMO partners rising, Akums is well-positioned to capture new opportunities and deliver sustainable growth in the coming quarters.

Sources: BSE Filings, Moneycontrol, Mint